[TORONTO, ON – December 5, 2025]
On International Neuroblastoma Awareness Day, Childhood Cancer Canada is proud and excited to announce an impactful investment to advance clinical trials and research collaborations for neuroblastoma, relapsed neuroblastoma, and refractory neuroblastoma across Canada. This investment will help accelerate access to promising therapies and expand opportunities for children facing one of the most complex and aggressive childhood cancers.
This investment will enable:
- Improved outcomes for all children diagnosed with neuroblastoma
- Open more clinical trials in Canada targeting neuroblastoma
- Reduce the backlog of pending trials and accelerate access to new treatment options
- Expand trial sites
- Strengthen Canadian-led research collaborations that contribute globally
Some of the studies supported through this initiative will be new to Canada. Others will help ensure that long-awaited clinical trials become accessible for more kids in Canada.
“Every child deserves the chance to benefit from the most promising treatments,” said Angie Ramalho, Executive Director, Childhood Cancer Canada “This investment is an important step forward. Progress depends on all of us.”
Tamy Bell, whose family lost their Son, Griffin to neuroblastoma had this to say about the announcement “We cannot help bring our son back. In fact, when he was diagnosed, we could not even help save him. As a parent, knowing you are not able to save your child is a very helpless feeling. This is why advancements in childhood cancer research are something we will always support in hopes of saving other children like ours.”
Childhood Cancer Canada is inviting Canadians to join this effort by making a donation to support neuroblastoma research. Community contributions will directly help open new trials, shorten research timelines, and bring renewed hope to children and families who urgently need better and safer treatment options.
Donate today and help support the next breakthrough in childhood cancer research.
More details to follow.